Stock SRPT SAREPTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq
Other stock markets
 21:00:00 08/05/2024 BST 		5-day change 1st Jan Change
132.6 USD -2.54% Intraday chart for Sarepta Therapeutics, Inc. +1.28% +37.49%
05-02 Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says MT
05-02 UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says
MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 EPS $0.73, vs. Street Est of $0.30
MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $413.5M, vs. Street Est of $370.5M
MT
Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours
MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
FDA greenlights Italfarmaco's drug for rare muscular dystrophy
RE
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market
MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M
MT
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37
MT
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Sarepta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Prices for new US drugs rose 35% in 2023, more than the previous year
RE
Exchange-Traded Funds Higher, Equity Futures Mixed Ahead of Inflation Data
MT
US FDA to review Sarepta's Duchenne gene therapy for traditional approval
RE
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication
CI
Wegovy packing supplier Catalent lays off 300 workers
RE
Sarepta says its experimental Duchenne drug more effective than older medicine
RE
Sarepta Therapeutics, Inc. Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
CI
Sarepta Therapeutics, Inc. Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
CI
Health Care Up as Merger Wave Continues -- Health Care Roundup
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. News Sarepta Therapeutics, Inc.
  5. Highlights